Drug Approval | May 04, 2022
Eugia Pharma receives USFDA approval for Bortezomib
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
Nystatin and Triamcinolone Acetonide ointment is indicated for the treatment of cutaneous candidiasis
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
Go-ahead for pivotal clinical trial which is expected to commence by March
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
The drug helps in managing cholesterol
Subscribe To Our Newsletter & Stay Updated
